Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis

• Published in: The European respiratory journal Vol. 27; no. 3; pp. 585 - 593
• Main Authors: Wylam, M. E, Ten, R, Prakash, U. B. S, Nadrous, H. F, Clawson, M. L, Anderson, P. M
• Format: Journal Article
• Language: English
• Published: Leeds Eur Respiratory Soc 01-03-2006; Maney
• Subjects: Administration, Inhalation; Adult; Biological and medical sciences; Female; Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage; Humans; Male; Medical sciences; Middle Aged; Pneumology; Pulmonary Alveolar Proteinosis - drug therapy; Retrospective Studies; Lung disease; Pulmonary alveolar proteinosis; Pulmonary surfactant; Respiratory disease; Granulocyte-macrophage colony-stimulating factor; Aerosols; Granulocyte macrophage colony stimulating factor; surfactant
• ISSN: 0903-1936; 1399-3003
• DOI: 10.1183/09031936.06.00058305

Recently, granulocyte-macrophage colony-stimulating factor (GM-CSF) auto-antibodies have been found in many patients with pulmonary alveolar proteinosis (PAP). The present study reports a retrospective case series of patients who used aerosolised GM-CSF in the treatment of idiopathic PAP. Between 1999 and 2003, 12 patients elected to receive aerosolised GM-CSF (250 microg b.i.d. every other week) in lieu of whole-lung lavage or observation. Patient characteristics, pulmonary function tests, arterial blood gas analysis, laboratory values and chest radiographs were extracted from the patient's medical records. Of the six patients tested, all had GM-CSF neutralising antibodies. Additionally, abnormalities in GM-CSF gene expression (one patient), receptor expression (two patients) and ability to upregulate adhesion molecules (one patient) were found. All patients except one had a positive response (mean improvements in arterial oxygen tension, alveolar-arterial oxygen gradient, carbon monoxide diffusing capacity of the lung and forced vital capacity were 17.1 mmHg, 18.4 mmHg, 16.6% pred and 13.5% pred, respectively). Two patients made a complete recovery and were disease free 1 and 2 yrs after discontinuing treatment. Four patients showed complete response to both the initial course or when treated again for recurrence after discontinuation of treatment. One patient required dose escalation (500 microg b.i.d.) with complete response. GM-CSF was well tolerated without late toxicity after median (range) follow-up of 30.5 (3-68) months. In conclusion, aerosolised granulocyte-macrophage colony-stimulating factor is safe and effective in treating pulmonary alveolar proteinosis providing an alternative to whole-lung lavage or subcutaneous granulocyte-macrophage colony-stimulating factor.